International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (19): 2720-2723.DOI: 10.3760/cma.j.issn.1007-1245.2023.19.013
• New Medical Advances • Previous Articles Next Articles
Research progress on the role of β -adrenergic receptor in tumor immunomodulation
Qin Mei, Yuan Xiaoli, Mi Tingtong, Wang Zhenbo
Department of Oncology, Binzhou Medical University Hospital, Binzhou 256600, China
Received:
2023-05-23
Online:
2023-10-01
Published:
2023-11-03
Contact:
Wang Zhenbo, Email: byfywzb@126.com
β-肾上腺素能受体在肿瘤免疫调节中的研究进展
秦梅 袁晓莉 米亭同 王振波
滨州医学院附属医院肿瘤科,滨州 256600
通讯作者:
王振波,Email:byfywzb@126.com
Qin Mei, Yuan Xiaoli, Mi Tingtong, Wang Zhenbo.
Research progress on the role of β -adrenergic receptor in tumor immunomodulation [J]. International Medicine and Health Guidance News, 2023, 29(19): 2720-2723.
秦梅 袁晓莉 米亭同 王振波.
β-肾上腺素能受体在肿瘤免疫调节中的研究进展 [J]. 国际医药卫生导报, 2023, 29(19): 2720-2723.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.imhgn.com/EN/10.3760/cma.j.issn.1007-1245.2023.19.013
[1] Qiao G, Chen M, Bucsek MJ, et al. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response[J].Front Immunol,2018,9:164.DOI:10.3389/fimmu.2018.00164. [2] Van Tits LJ, Michel MC, Grosse-Wilde H, et al. Catecholamines increase lymphocyte beta 2-adrenergic receptors via a beta 2-adrenergic, spleen-dependent process[J].Am J Physiol,1990,258(1 Pt 1):E191-202.DOI:10.1152/ajpendo.1990.258.1.E191. [3] 李晓燕,李亚星,贾漪涛. β-肾上腺素能受体在肿瘤发生和发展中的研究进展[J]. 肿瘤,2021,41(9):650-656.DOI:10.3781/j.issn.1000-7431.2021.2010-0897. [4] Fu T, Dai LJ, Wu SY, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response[J].J Hematol Oncol,2021,14(1):98.DOI:10.1186/s13045-021-01103-4. [5] Lv B, Wang Y, Ma D, et al. Immunotherapy: reshape the tumor immune microenvironment[J].Front Immunol,2022,13:844142.DOI:10.3389/fimmu.2022.844142. [6] Gandhi S, Pandey MR, Attwood K, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity[J]. Clin Cancer Res,2021,27(1):87-95.DOI:10.1158/1078-0432.CCR-20-2381. [7] Kennedy OJ, Kicinski M, Valpione S, et al. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma[J].Eur J Cancer,2022,165:97-112.DOI:10.1016/j.ejca.2022.01.017. [8] Kokolus KM, Zhang Y, Sivik JM, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice[J].Oncoimmunology,2017,7(3):e1405205.DOI:10.1080/2162402X.2017.1405205. [9] Yang C, He Y, Chen F, et al. Leveraging β-adrenergic receptor signaling blockade for improved cancer immunotherapy through biomimetic nanovaccine[J].Small,2023,19(14):e2207029.DOI:10.1002/smll.202207029. [10] Daher C, Vimeux L, Stoeva R, et al. Blockade of β-adrenergic receptors improves CD8+ T-cell priming and cancer vaccine efficacy[J].Cancer Immunol Res,2019,7(11):1849-1863.DOI:10.1158/2326-6066.CIR-18-0833. [11] Hinkle L, Liu Y, Meng C, et al. The sympathetic nervous system modulates cancer vaccine activity through monocyte-derived cells[J].J Immunol,2021,207(12):3131-3140.DOI:10.4049/jimmunol.2100719. [12] Nissen MD, Sloan EK, Mattarollo SR. β-adrenergic signaling impairs antitumor CD8+ T-cell responses to B-cell lymphoma immunotherapy[J].Cancer Immunol Res,2018,6(1):98-109.DOI:10.1158/2326-6066.CIR-17-0401. [13] De Cicco P, Ercolano G, Ianaro A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion[J].Front Immunol,2020,11:1680.DOI:10.3389/fimmu.2020.01680. [14] Mohammadpour H, MacDonald CR, Qiao G, et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells[J].J Clin Invest,2019,129(12):5537-5552.DOI:10.1172/JCI129502. [15] Mohammadpour H, MacDonald CR, McCarthy PL, et al. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME[J].Cell Rep,2021,37(4):109883.DOI:10.1016/j.celrep.2021.109883. [16] Kokolus KM, Capitano ML, Lee CT, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature[J].Proc Natl Acad Sci U S A,2013,110(50):20176-20181.DOI:10.1073/pnas.1304291110. [17] Qiao G, Bucsek MJ, Winder NM, et al. β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress[J].Cancer Immunol Immunother,2019,68(1):11-22.DOI:10.1007/s00262-018-2243-8. [18] Wang JX, Choi SYC, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity[J].Int J Mol Sci,2020,21(21):8363.DOI:10.3390/ijms21218363. [19] Qiao G, Chen M, Mohammadpour H, et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment[J].Cancer Immunol Res,2021,9(6):651-664.DOI:10.1158/2326-6066.CIR-20-0445. [20] Zou S, Tong Q, Liu B, et al. Targeting STAT3 in cancer immunotherapy[J].Mol Cancer,2020,19(1):145.DOI:10.1186/s12943-020-01258-7. [21] Balligand JL. β-adrenergic receptors cooperate with transcription factors: the "STAT" of their union[J].Circulation,2016,133(1):4-7.DOI:10.1161/CIRCULATIONAHA.115.019860. [22] Rébé C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response[J].Cancers (Basel),2019,11(9):1280.DOI:10.3390/cancers11091280. [23] Najafi M, Hashemi Goradel N, Farhood B, et al. Macrophage polarity in cancer: a review[J].J Cell Biochem,2019,120(3):2756-2765.DOI:10.1002/jcb.27646. [24] Qin JF, Jin FJ, Li N, et al. Adrenergic receptor β2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment[J].BMB Rep,2015,48(5):295-300.DOI:10.5483/bmbrep.2015.48.5.008. [25] Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer[J].Cancer Res,2010,70(18):7042-7052.DOI:10.1158/0008-5472.CAN-10-0522. [26] Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth[J].Oncotarget,2015,6(6):4266-4273.DOI:10.18632/oncotarget.2887. [27] 胡绍雯,朱惠芳. NK细胞在肿瘤免疫治疗中的研究进展[J].中国免疫学杂志,2023,39(6):1318-1325.DOI:10.3969/j.issn.1000-484X.2023.06.043. [28] Prager I, Liesche C, van Ooijen H, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing[J].J Exp Med,2019,216(9):2113-2127.DOI:10.1084/jem.20181454. [29] Hu D, Shen W, Gong C, et al. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer[J].J Cell Mol Med,2021,25(6):2900-2908.DOI:10.1111/jcmm.16320. [30] Wieduwild E, Girard-Madoux MJ, Quatrini L, et al. β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection[J].J Exp Med,2020,217(4):e20190554.DOI:10.1084/jem.20190554. [31] Singh A, Ranjan A. Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity[J].Front Immunol,2023,14:1141712.DOI:10.3389/fimmu.2023.1141712. [32] Huang X, Le W, Chen Q, et al. Suppression of the innate cancer-killing activity in human granulocytes by stress reaction as a possible mechanism for affecting cancer development[J].Stress,2020,23(1):87-96.DOI:10.1080/10253890.2019.1645112. [33] Perego M, Tyurin VA, Tyurina YY, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils[J].Sci Transl Med,2020,12(572):eabb5817.DOI:10.1126/scitranslmed.abb5817. |
[1] |
Ke Jin, Wang Hengshi, Zhang Shanlan.
Clinical analysis of immune-related adverse events induced by camrelizumab [J]. International Medicine and Health Guidance News, 2023, 29(9): 1258-1262. |
[2] |
Wang Zechuan, Huang Yueqin.
Advances in targeted drug therapy for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(8): 1045-1048. |
[3] |
Xu Shijie, Luo Zebin, Chen Xiaodong.
Application and progress of CT pulmonary angiography in diagnosis and treatment of pulmonary embolism [J]. International Medicine and Health Guidance News, 2023, 29(8): 1053-1056. |
[4] |
Zhang Heng, Pan Guangtao, Yin Ming, Zhang Ping, Yin Xia.
Progress in autologous fat transplantation in plastic surgery [J]. International Medicine and Health Guidance News, 2023, 29(7): 889-892. |
[5] |
Wu Xuemei, Zhang Yujie, Xie Shenghua.
Psoriasis and its cardiovascular system comorbidities [J]. International Medicine and Health Guidance News, 2023, 29(4): 453-456. |
[6] |
Yuan Xiaoli, Wang Zhenbo.
Research progress on tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma [J]. International Medicine and Health Guidance News, 2023, 29(3): 310-314. |
[7] |
Ling Juan, Zeng Huilan.
Progress of bispecific antibodies in relapsed/refractory multiple myeloma [J]. International Medicine and Health Guidance News, 2023, 29(3): 319-323. |
[8] |
Zhan Xia, Li Zhixia.
One case of idiopathic hypertrophic cranial and spinal pachymeningitis [J]. International Medicine and Health Guidance News, 2023, 29(3): 430-433. |
[9] |
Shang Xue, Zhao Jiahao, Li Xinxi, Zhu Hui, Zhao Ke, Liu Zhenxing, Xu Huipu.
Research progress of GSDMD-mediated pyrodeath in atrial fibrillation [J]. International Medicine and Health Guidance News, 2023, 29(20): 2825-2828. |
[10] |
Wang Yaoyao, Ma Xiufang.
Research progress on immune-mediated inner ear disease [J]. International Medicine and Health Guidance News, 2023, 29(20): 2833-2836. |
[11] |
Wang Lu, Xie Henan, Zhao Qimei, Xie Zheng.
Research progress of assessment tools for adults' oral health literacy assessment [J]. International Medicine and Health Guidance News, 2023, 29(20): 2836-2841. |
[12] |
Chu Linlin, Wang Na, Hao Jiahui, Sun Xiao, Liu Chengxia.
Research progress of polyamines and Helicobacter pylori-induced gastric cancer [J]. International Medicine and Health Guidance News, 2023, 29(20): 2848-2851. |
[13] |
Li Zongrui, Liu Weipeng, Hu Baoguang.
Research progress of NKG2D and its ligands in treatment of gastric cancer [J]. International Medicine and Health Guidance News, 2023, 29(20): 2852-2856. |
[14] |
Yang Lina, Wang Yu, Xia Bo.
Research progress on clinical application of Lao Moxibustion [J]. International Medicine and Health Guidance News, 2023, 29(2): 154-. |
[15] |
Ma Xiaoying, Yang Juan, Zheng Sheng.
Research progress in chronic liver disease and iron metabolism [J]. International Medicine and Health Guidance News, 2023, 29(19): 2724-2727. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||